Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8322 results
Found 8322 results.

Adult

Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Robbins GK, Testa MA, Su M, et al. "Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384." HIV Clin Trials. 2013;14(5):235-53.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.
Dooley KE, Park J-G, Swindells S, et al. "Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267." J. Acquir. Immune Defic. Syndr.. 2012;59(5):455-62.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Anthony DD, Conry SJ, Medvik K, et al. "Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection." J. Infect. Dis.. 2012;206(6):969-73.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Amorosa VK, Luetkemeyer A, Kang M, et al. "Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial." HIV Clin Trials. 2013;14(6):274-83.
Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO. "Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis." Antimicrob. Agents Chemother.. 2013;57(6):2780-7.
Kojic EMilunka, Kang M, Cespedes MS, et al. "Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women." Clin. Infect. Dis.. 2014;59(1):127-35.
Périssé ARS, Smeaton L, Chen Y, et al. "Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease." PLoS ONE. 2013;8(12):e83643.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Smith DM, Strain MC, Frost SDW, et al. "Lack of neutralizing antibody response to HIV-1 predisposes to superinfection." Virology. 2006;355(1):1-5.
Yonkers NL, Rodriguez B, Milkovich KA, et al. "TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection." J. Immunol.. 2007;178(7):4436-44.
Blackard JT, Kang M, J St Clair B, et al. "Viral factors associated with cytokine expression during HCV/HIV co-infection." J. Interferon Cytokine Res.. 2007;27(4):263-9.
Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE. "Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients." HIV Clin Trials. 2012;13(2):70-82.
Robertson K, Kumwenda J, Supparatpinyo K, et al. "A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings." J. Neurovirol.. 2011;17(5):438-47.
Mulligan K, Zackin R, Von Roenn JH, et al. "Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial." J. Clin. Endocrinol. Metab.. 2007;92(2):563-70.
Albrecht M, A Mukherjee L, Tierney C, et al. "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study." HIV Clin Trials. 2011;12(4):201-14.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
Behler CM, Vittinghoff E, Lin F, et al. "Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects." Clin. Infect. Dis.. 2007;44(10):1375-83.
Swindells S, Komarow L, Tripathy S, et al. "Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2013;17(4):532-9.
Krishnan S, Schouten JT, Atkinson B, et al. "Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2012;61(3):381-9.
Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Hulgan T, Donahue JP, Smeaton L, et al. "Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors." Eur. J. Clin. Pharmacol.. 2009;65(11):1081-8.
Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Lockman S, Hughes MD, McIntyre J, et al. "Antiretroviral therapies in women after single-dose nevirapine exposure." N. Engl. J. Med.. 2010;363(16):1499-509.
Schwarze-Zander C, Blackard JT, Zheng H, et al. "GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype." J. Infect. Dis.. 2006;194(4):410-9.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
Basham RJ, Richardson DM, Sutcliffe CB, Haas DW. "Effect of HIV-1 infection on human DNA yield from saliva." HIV Clin Trials. 2009;10(4):282-5.

Pages